KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $108.2 million.

  • Alnylam Pharmaceuticals' Share-based Compensation rose 13624.79% to $108.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $368.2 million, marking a year-over-year increase of 6555.46%. This contributed to the annual value of $272.1 million for FY2024, which is 2273.73% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Share-based Compensation stood at $108.2 million, which was up 13624.79% from $111.7 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Share-based Compensation registered a high of $128.1 million during Q3 2022, and its lowest value of $29.3 million during Q1 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Share-based Compensation averaged around $61.4 million, with its median value being $45.8 million (2024).
  • In the last 5 years, Alnylam Pharmaceuticals' Share-based Compensation soared by 28396.62% in 2022 and then crashed by 5009.52% in 2023.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Share-based Compensation stood at $44.6 million in 2021, then decreased by 4.07% to $42.8 million in 2022, then decreased by 1.81% to $42.0 million in 2023, then soared by 118.23% to $91.6 million in 2024, then rose by 18.08% to $108.2 million in 2025.
  • Its Share-based Compensation was $108.2 million in Q3 2025, compared to $111.7 million in Q2 2025 and $56.7 million in Q1 2025.